Lexicon Pharmaceuticals NASDAQ: LXRX reported a wider second-quarter loss as revenue declined sharply from the prior-year period, while the company highlighted completed enrollment in its Phase III SONATA-HCM trial and outlined plans to resubmit a new drug application for ZYNQUISTA in type 1 diabetes during the fourth quarter.Get LXRX alerts:Total revenue for the quarter ended June 30 was $0.7 million, compared with $28.9 million a year earlier. Second-quarter 2026 revenue represented net sales of INPEFA, w ...